John Blankenhorn

John Blankenhorn

InvestorPlace Contributor

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

The 3 Best Self-Driving Car Stocks to Buy In July

By John Blankenhorn, InvestorPlace Contributor

Here are 3 self-driving car stocks to add to your portfolio if you see the mode of transportation as the wave of the future.

3 Metaverse Stocks That Should Make Your July Must-Sell List

By John Blankenhorn, InvestorPlace Contributor

The AI hype has superseded the metaverse hype. So now is a good time to clean out your portfolio and sell these three metaverse stocks.

Time to Evolve: 3 Synthetic Biology Stocks to Sell Off Now

By John Blankenhorn, InvestorPlace Contributor

The biotech boom has become a biotech bust. Many companies still have further to fall, so sell these three before they hit rock bottom.

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom

By John Blankenhorn, InvestorPlace Contributor

AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.

3 EV Stocks That Just Have No More Hope Left

By John Blankenhorn, InvestorPlace Contributor

Not every electric vehicle company will survive. Here are three EV stocks you'll want to sell before they go bankrupt or just fade away.

Load More